Does the media favor MRK or SMMT?

In the previous week, Merck & Co., Inc. had 40 more articles in the media than Summit Therapeutics. MarketBeat recorded 49 mentions for Merck & Co., Inc. and 9 mentions for Summit Therapeutics. Summit Therapeutics' average media sentiment score of 1.12 beat Merck & Co., Inc.'s score of 1.05 indicating that Summit Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Merck & Co., Inc. 28 Very Positive mention(s) 8 Positive mention(s) 7 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Positive Summit Therapeutics 6 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation & earnings, SMMT or LPA?

Logistic Properties of the Americas has higher revenue and earnings than Summit Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Summit Therapeutics N/A N/A -$1.08B -$1.12 N/A Logistic Properties of the Americas $50.13M 2.13 $10.50M N/A N/A

Does the media favor SMMT or LPA?

In the previous week, Summit Therapeutics had 3 more articles in the media than Logistic Properties of the Americas. MarketBeat recorded 9 mentions for Summit Therapeutics and 6 mentions for Logistic Properties of the Americas. Summit Therapeutics' average media sentiment score of 1.12 beat Logistic Properties of the Americas' score of 0.28 indicating that Summit Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Summit Therapeutics 6 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Logistic Properties of the Americas 1 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to SMMT or NTRA?

In the previous week, Natera had 10 more articles in the media than Summit Therapeutics. MarketBeat recorded 19 mentions for Natera and 9 mentions for Summit Therapeutics. Natera's average media sentiment score of 1.21 beat Summit Therapeutics' score of 1.12 indicating that Natera is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Summit Therapeutics 6 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Natera 11 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings & valuation, RVMD or SMMT?

Revolution Medicines is trading at a lower price-to-earnings ratio than Summit Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Revolution Medicines N/A N/A -$1.13B -$8.82 N/A Summit Therapeutics N/A N/A -$1.08B -$1.12 N/A

Is RVMD or SMMT more profitable?

Revolution Medicines' return on equity of -88.20% beat Summit Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Revolution Medicines N/A -88.20% -57.85% Summit Therapeutics N/A -168.94% -141.92%

Does the media refer more to RVMD or SMMT?

In the previous week, Revolution Medicines had 4 more articles in the media than Summit Therapeutics. MarketBeat recorded 13 mentions for Revolution Medicines and 9 mentions for Summit Therapeutics. Revolution Medicines' average media sentiment score of 1.20 beat Summit Therapeutics' score of 1.12 indicating that Revolution Medicines is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Revolution Medicines 10 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Summit Therapeutics 6 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor ALNY or SMMT?

In the previous week, Alnylam Pharmaceuticals had 5 more articles in the media than Summit Therapeutics. MarketBeat recorded 14 mentions for Alnylam Pharmaceuticals and 9 mentions for Summit Therapeutics. Summit Therapeutics' average media sentiment score of 1.12 beat Alnylam Pharmaceuticals' score of 1.12 indicating that Summit Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alnylam Pharmaceuticals 8 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Summit Therapeutics 6 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Summit Therapeutics (SMMT) Competitors

$17.55 +0.55 (+3.24%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$17.66 +0.11 (+0.63%)

As of 09/11/2026 07:58 PM Eastern

Compare

SMMT vs. MRK, LPA, NTRA, RVMD, and ALNY

Should you buy Summit Therapeutics stock or one of its competitors? Summit Therapeutics's main competitors and comparable companies include Merck & Co., Inc. (MRK), Logistic Properties of the Americas (LPA), Natera (NTRA), Revolution Medicines (RVMD), and Alnylam Pharmaceuticals (ALNY). Companies are selected based on similarities in market, industry, and size.

How does Summit Therapeutics compare to Merck & Co., Inc.?

Merck & Co., Inc. (NYSE:MRK) and Summit Therapeutics (NASDAQ:SMMT) are both large-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, media sentiment, earnings, risk and dividends.

Merck & Co., Inc. presently has a consensus target price of $151.32, suggesting a potential upside of 5.07%. Summit Therapeutics has a consensus target price of $25.91, suggesting a potential upside of 47.63%. Given Summit Therapeutics' higher possible upside, analysts clearly believe Summit Therapeutics is more favorable than Merck & Co., Inc..

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Merck & Co., Inc.	0 Sell rating(s)	8 Hold rating(s)	17 Buy rating(s)	0 Strong Buy rating(s)	2.68
Summit Therapeutics	1 Sell rating(s)	8 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.47

76.1% of Merck & Co., Inc. shares are held by institutional investors. Comparatively, 4.6% of Summit Therapeutics shares are held by institutional investors. 0.2% of Merck & Co., Inc. shares are held by insiders. Comparatively, 83.5% of Summit Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Merck & Co., Inc. has higher revenue and earnings than Summit Therapeutics. Summit Therapeutics is trading at a lower price-to-earnings ratio than Merck & Co., Inc., indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Merck & Co., Inc.	$65.01B	5.47	$18.25B	$1.25	115.22
Summit Therapeutics	N/A	N/A	-$1.08B	-$1.12	N/A

Merck & Co., Inc. has a beta of 0.21, indicating that its stock price is 79% less volatile than the broader market. Comparatively, Summit Therapeutics has a beta of -1.24, indicating that its stock price is 224% less volatile than the broader market.

In the previous week, Merck & Co., Inc. had 40 more articles in the media than Summit Therapeutics. MarketBeat recorded 49 mentions for Merck & Co., Inc. and 9 mentions for Summit Therapeutics. Summit Therapeutics' average media sentiment score of 1.12 beat Merck & Co., Inc.'s score of 1.05 indicating that Summit Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Merck & Co., Inc.	28 Very Positive mention(s)	8 Positive mention(s)	7 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Positive
Summit Therapeutics	6 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Merck & Co., Inc. has a net margin of 4.77% compared to Summit Therapeutics' net margin of 0.00%. Merck & Co., Inc.'s return on equity of 16.73% beat Summit Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Merck & Co., Inc.	4.77%	16.73%	6.13%
Summit Therapeutics	N/A	-168.94%	-141.92%

Summary

Merck & Co., Inc. beats Summit Therapeutics on 12 of the 16 factors compared between the two stocks.

How does Summit Therapeutics compare to Logistic Properties of the Americas?

Summit Therapeutics (NASDAQ:SMMT) and Logistic Properties of the Americas (NYSEAMERICAN:LPA) are related companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, institutional ownership, media sentiment, profitability and earnings.

4.6% of Summit Therapeutics shares are held by institutional investors. Comparatively, 42.7% of Logistic Properties of the Americas shares are held by institutional investors. 83.5% of Summit Therapeutics shares are held by insiders. Comparatively, 32.0% of Logistic Properties of the Americas shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Logistic Properties of the Americas has a net margin of 30.97% compared to Summit Therapeutics' net margin of 0.00%. Logistic Properties of the Americas' return on equity of 0.46% beat Summit Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Summit Therapeutics	N/A	-168.94%	-141.92%
Logistic Properties of the Americas	30.97%	0.46%	0.21%

Logistic Properties of the Americas has higher revenue and earnings than Summit Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Summit Therapeutics	N/A	N/A	-$1.08B	-$1.12	N/A
Logistic Properties of the Americas	$50.13M	2.13	$10.50M	N/A	N/A

Summit Therapeutics has a beta of -1.24, suggesting that its share price is 224% less volatile than the broader market. Comparatively, Logistic Properties of the Americas has a beta of 5.4, suggesting that its share price is 440% more volatile than the broader market.

In the previous week, Summit Therapeutics had 3 more articles in the media than Logistic Properties of the Americas. MarketBeat recorded 9 mentions for Summit Therapeutics and 6 mentions for Logistic Properties of the Americas. Summit Therapeutics' average media sentiment score of 1.12 beat Logistic Properties of the Americas' score of 0.28 indicating that Summit Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Summit Therapeutics	6 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Logistic Properties of the Americas	1 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summit Therapeutics currently has a consensus price target of $25.91, indicating a potential upside of 47.63%. Logistic Properties of the Americas has a consensus price target of $7.50, indicating a potential upside of 121.89%. Given Logistic Properties of the Americas' higher probable upside, analysts plainly believe Logistic Properties of the Americas is more favorable than Summit Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Summit Therapeutics	1 Sell rating(s)	8 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.47
Logistic Properties of the Americas	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Logistic Properties of the Americas beats Summit Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Summit Therapeutics compare to Natera?

Summit Therapeutics (NASDAQ:SMMT) and Natera (NASDAQ:NTRA) are both large-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, risk, media sentiment, profitability, dividends, valuation, institutional ownership and earnings.

Natera has higher revenue and earnings than Summit Therapeutics. Natera is trading at a lower price-to-earnings ratio than Summit Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Summit Therapeutics	N/A	N/A	-$1.08B	-$1.12	N/A
Natera	$2.31B	20.56	-$208.16M	-$1.36	N/A

Summit Therapeutics currently has a consensus target price of $25.91, suggesting a potential upside of 47.63%. Natera has a consensus target price of $330.83, suggesting a potential upside of 0.58%. Given Summit Therapeutics' higher possible upside, analysts plainly believe Summit Therapeutics is more favorable than Natera.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Summit Therapeutics	1 Sell rating(s)	8 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.47
Natera	1 Sell rating(s)	4 Hold rating(s)	16 Buy rating(s)	2 Strong Buy rating(s)	2.83

In the previous week, Natera had 10 more articles in the media than Summit Therapeutics. MarketBeat recorded 19 mentions for Natera and 9 mentions for Summit Therapeutics. Natera's average media sentiment score of 1.21 beat Summit Therapeutics' score of 1.12 indicating that Natera is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Summit Therapeutics	6 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Natera	11 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summit Therapeutics has a net margin of 0.00% compared to Natera's net margin of -7.11%. Natera's return on equity of -11.38% beat Summit Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Summit Therapeutics	N/A	-168.94%	-141.92%
Natera	-7.11%	-11.38%	-7.87%

4.6% of Summit Therapeutics shares are owned by institutional investors. Comparatively, 99.9% of Natera shares are owned by institutional investors. 83.5% of Summit Therapeutics shares are owned by company insiders. Comparatively, 5.1% of Natera shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summit Therapeutics has a beta of -1.24, indicating that its share price is 224% less volatile than the broader market. Comparatively, Natera has a beta of 1.54, indicating that its share price is 54% more volatile than the broader market.

Summary

Natera beats Summit Therapeutics on 11 of the 16 factors compared between the two stocks.

How does Summit Therapeutics compare to Revolution Medicines?

Revolution Medicines (NASDAQ:RVMD) and Summit Therapeutics (NASDAQ:SMMT) are both large-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, earnings, dividends, media sentiment, valuation, profitability and institutional ownership.

Revolution Medicines has a beta of 1.4, suggesting that its stock price is 40% more volatile than the broader market. Comparatively, Summit Therapeutics has a beta of -1.24, suggesting that its stock price is 224% less volatile than the broader market.

Revolution Medicines is trading at a lower price-to-earnings ratio than Summit Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Revolution Medicines	N/A	N/A	-$1.13B	-$8.82	N/A
Summit Therapeutics	N/A	N/A	-$1.08B	-$1.12	N/A

In the previous week, Revolution Medicines had 4 more articles in the media than Summit Therapeutics. MarketBeat recorded 13 mentions for Revolution Medicines and 9 mentions for Summit Therapeutics. Revolution Medicines' average media sentiment score of 1.20 beat Summit Therapeutics' score of 1.12 indicating that Revolution Medicines is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Revolution Medicines	10 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Summit Therapeutics	6 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Revolution Medicines currently has a consensus target price of $226.17, suggesting a potential upside of 10.99%. Summit Therapeutics has a consensus target price of $25.91, suggesting a potential upside of 47.63%. Given Summit Therapeutics' higher possible upside, analysts plainly believe Summit Therapeutics is more favorable than Revolution Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Revolution Medicines	1 Sell rating(s)	1 Hold rating(s)	17 Buy rating(s)	2 Strong Buy rating(s)	2.95
Summit Therapeutics	1 Sell rating(s)	8 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.47

94.3% of Revolution Medicines shares are held by institutional investors. Comparatively, 4.6% of Summit Therapeutics shares are held by institutional investors. 7.6% of Revolution Medicines shares are held by insiders. Comparatively, 83.5% of Summit Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Revolution Medicines' return on equity of -88.20% beat Summit Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Revolution Medicines	N/A	-88.20%	-57.85%
Summit Therapeutics	N/A	-168.94%	-141.92%

Summary

Revolution Medicines beats Summit Therapeutics on 9 of the 14 factors compared between the two stocks.

How does Summit Therapeutics compare to Alnylam Pharmaceuticals?

Alnylam Pharmaceuticals (NASDAQ:ALNY) and Summit Therapeutics (NASDAQ:SMMT) are both large-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, institutional ownership, profitability, valuation, risk, dividends and earnings.

Alnylam Pharmaceuticals presently has a consensus target price of $376.67, indicating a potential upside of 51.47%. Summit Therapeutics has a consensus target price of $25.91, indicating a potential upside of 47.63%. Given Alnylam Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Alnylam Pharmaceuticals is more favorable than Summit Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alnylam Pharmaceuticals	0 Sell rating(s)	5 Hold rating(s)	17 Buy rating(s)	2 Strong Buy rating(s)	2.88
Summit Therapeutics	1 Sell rating(s)	8 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.47

In the previous week, Alnylam Pharmaceuticals had 5 more articles in the media than Summit Therapeutics. MarketBeat recorded 14 mentions for Alnylam Pharmaceuticals and 9 mentions for Summit Therapeutics. Summit Therapeutics' average media sentiment score of 1.12 beat Alnylam Pharmaceuticals' score of 1.12 indicating that Summit Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alnylam Pharmaceuticals	8 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Summit Therapeutics	6 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Alnylam Pharmaceuticals has a net margin of 15.26% compared to Summit Therapeutics' net margin of 0.00%. Alnylam Pharmaceuticals' return on equity of 84.93% beat Summit Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alnylam Pharmaceuticals	15.26%	84.93%	14.30%
Summit Therapeutics	N/A	-168.94%	-141.92%

Alnylam Pharmaceuticals has higher revenue and earnings than Summit Therapeutics. Summit Therapeutics is trading at a lower price-to-earnings ratio than Alnylam Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alnylam Pharmaceuticals	$3.71B	8.96	$313.75M	$5.38	46.22
Summit Therapeutics	N/A	N/A	-$1.08B	-$1.12	N/A

Alnylam Pharmaceuticals has a beta of 0.31, meaning that its share price is 69% less volatile than the broader market. Comparatively, Summit Therapeutics has a beta of -1.24, meaning that its share price is 224% less volatile than the broader market.

93.0% of Alnylam Pharmaceuticals shares are owned by institutional investors. Comparatively, 4.6% of Summit Therapeutics shares are owned by institutional investors. 0.9% of Alnylam Pharmaceuticals shares are owned by insiders. Comparatively, 83.5% of Summit Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Alnylam Pharmaceuticals beats Summit Therapeutics on 14 of the 16 factors compared between the two stocks.

Get Summit Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SMMT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SMMT vs. The Competition

Export

Metric	Summit Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$14.00B	$3.85B	$7.15B	$12.72B
Dividend Yield	N/A	3.63%	2.56%	11.15%
P/E Ratio	-15.67	14.18	274.10	25.29
Price / Sales	N/A	1,477.55	655.45	98.96
Price / Cash	N/A	106.68	77.04	51.44
Price / Book	20.65	15.12	10.33	6.20
Net Income	-$1.08B	-$22.86M	$3.50B	$358.50M
7 Day Performance	-0.28%	-4.35%	-3.33%	-2.35%
1 Month Performance	16.23%	-0.03%	-0.41%	-2.77%
1 Year Performance	-7.34%	40.63%	19.22%	7.63%

Summit Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SMMT Summit Therapeutics	3.6748 of 5 stars	$17.55 +3.2%	$25.91 +47.6%	-5.6%	$14.00B	N/A	N/A	265	Positive News Analyst Forecast
MRK Merck & Co., Inc.	4.4859 of 5 stars	$150.37 -1.3%	$148.60 -1.2%	+69.2%	$375.85B	$65.01B	120.30	75,000	Trending News Analyst Forecast
LPA Logistic Properties of the Americas	4.5961 of 5 stars	$3.07 -1.9%	$7.50 +144.3%	-48.9%	$98.96M	$50.13M	5.69	30	News Coverage Negative News Short Interest Decrease
NTRA Natera	2.1519 of 5 stars	$328.18 +0.2%	$319.38 -2.7%	+89.2%	$47.23B	$2.31B	N/A	6,140	Positive News Analyst Forecast
RVMD Revolution Medicines	2.9764 of 5 stars	$210.02 -0.4%	$200.74 -4.4%	+340.7%	$45.20B	$11.58M	N/A	250	Positive News Analyst Forecast Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SMMT) was last updated on 9/12/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Summit Therapeutics (SMMT) Competitors

SMMT vs. MRK, LPA, NTRA, RVMD, and ALNY

How does Summit Therapeutics compare to Merck & Co., Inc.?

Summary

How does Summit Therapeutics compare to Logistic Properties of the Americas?

Summary

How does Summit Therapeutics compare to Natera?

Summary

How does Summit Therapeutics compare to Revolution Medicines?

Summary

How does Summit Therapeutics compare to Alnylam Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SMMT vs. The Competition

Summit Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Summit Therapeutics (SMMT) Competitors

SMMT vs. MRK, LPA, NTRA, RVMD, and ALNY

How does Summit Therapeutics compare to Merck & Co., Inc.?

Do analysts prefer MRK or SMMT?

Do insiders & institutionals have more ownership in MRK or SMMT?

Which has higher valuation & earnings, MRK or SMMT?

Which has more volatility & risk, MRK or SMMT?

Does the media favor MRK or SMMT?

Is MRK or SMMT more profitable?

Summary

How does Summit Therapeutics compare to Logistic Properties of the Americas?

Do institutionals and insiders hold more shares of SMMT or LPA?

Is SMMT or LPA more profitable?

Which has higher valuation & earnings, SMMT or LPA?

Which has more risk & volatility, SMMT or LPA?

Does the media favor SMMT or LPA?

Do analysts recommend SMMT or LPA?

Summary

How does Summit Therapeutics compare to Natera?

Which has better earnings and valuation, SMMT or NTRA?

Do analysts recommend SMMT or NTRA?

Does the media refer more to SMMT or NTRA?

Is SMMT or NTRA more profitable?

Do institutionals & insiders hold more shares of SMMT or NTRA?

Which has more risk and volatility, SMMT or NTRA?

Summary

How does Summit Therapeutics compare to Revolution Medicines?

Which has more risk and volatility, RVMD or SMMT?

Which has better earnings & valuation, RVMD or SMMT?

Does the media refer more to RVMD or SMMT?

Do analysts rate RVMD or SMMT?

Do institutionals and insiders have more ownership in RVMD or SMMT?

Is RVMD or SMMT more profitable?

Summary

How does Summit Therapeutics compare to Alnylam Pharmaceuticals?

Do analysts recommend ALNY or SMMT?

Does the media favor ALNY or SMMT?

Is ALNY or SMMT more profitable?

Which has better valuation & earnings, ALNY or SMMT?

Which has more risk & volatility, ALNY or SMMT?

Do insiders and institutionals believe in ALNY or SMMT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SMMT vs. The Competition

Summit Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools